Skip to main content

Table 2 Demographic and clinical features of total cohort and AIT subgroups in patients who completed or withdrew from the AIT program

From: Impact on quality of life and safety of sublingual and subcutaneous immunotherapy in children with severe house dust mite and pollen-associated allergic rhinoconjunctivitis

 

Total cohort

Pollen SCIT

Pollen SLIT

HDM SLIT

Completed

Withdrew

P-value

Completed

Withdrew

P-value

Completed

Withdrew

P-value

Completed

Withdrew

P-value

Frequency

118 (71%)

49 (29%)

 

70 (82%)

15 (18%)

 

13 (62%)

8 (38%)

 

35 (49%)

26 (51%)

 

Age (years)

Median (IQR)

12 (10–14)

14 (12–16)

< 0.001

13 (11–14)

15 (14–16)

< 0.001

11 (10–15)

12 (9–16)

0.5

10 (9–13)

14 (11–16)

0.003

Gender

 Male

86 (73%)

29 (59%)

0.08

55 (79%)

9 (60%)

0.2

9 (69%)

6 (75%)

1.0a

22 (63%)

14 (54%)

0.5

 Female

32 (27%)

20 (41%)

15 (21%)

6 (40%)

4 (31%)

2 (25%)

13 (37%)

12 (46%)

Race

 White European

87 (74%)

31 (26%)

0.1

57 (81%)

12 (80%)

0.6a

13 (100%)

7 (88%)

0.4a

17 (49%)

11 (42%)

0.6

 Other

30 (61%)

49 (39%)

13 (19%)

3 (20%)

0 (0%)

1 (12%)

18 (51%)

15 (58%)

AR symptoms

 Eyes

8 (7%)

3 (6%)

1.0a

3 (4%)

1 (7%)

0.8a

3 (23%)

1 (12%)

1.0

2 (6%)

1 (4%)

0.9a

 Nose

11 (9%)

4 (8%)

4 (6%)

0 (0%)

1 (8%)

1 (12%)

6 (17%)

3 (11%)

 Eyes + nose

99 (84%)

42 (86%)

63 (90%)

14 (93%)

9 (69%)

6 (75%)

27 (77%)

22 (85%)

Medication

 OA only

3 (3%)

0

1.0a

1 (1%)

0%

0.3a

0 (0%)

0 (0%)

0.4a

2 (6%)

0 (0%)

0.6a

 OA + Adjuncts

107 (90%)

47 (88%)

65 (93%)

12 (80%)

13 (100%)

7 (88%)

29 (83%)

24 (92%)

 Systemics

8 (7%)

6 (12%)

4 (6%)

3 (20%)

0 (0%)

1 (12%)

4 (11%)

2 (8%)

Other atopic disease

 Asthma

55 (47%)

17 (35%)

0.2

35 (50%)

6 (40%)

0.2

6 (46%)

2 (25%)

1.0a

14 (40%)

9 (35%)

1.0a

 AD

11 (9%)

3 (6%)

7 (10%)

1 (7%)

0 (0%)

0 (0%)

4 (11%)

2 (8%)

 Asthma + AD

29 (25%)

17 (35%)

12 (17%)

6 (40%)

2 (15%)

1 (12%)

15 (43%)

10 (38%)118

Mono-sensitised to AIT

 Yes

57 (48%)

14 (29%)

0.02

43 (61%)

4 (27%)

0.03

6 (46%)

3 (38%)

1a

8 (23%)

7 (27%)

0.7

 No

61 (52%)

35 (71%)

27 (39%)

11 (73%)

7 (54%)

5 (62%)

27 (77%)

19 (73%)

Median baseline RQLQ (IQR)

65 (36–89)

59 (38–85)

0.5

77 (38–97)

75 (41–89)

0.5

56 (45–115)

80 (80–80)

0.9

51 (33–79)

15 (43%)

0.3

Median baseline VAS (IQR)

7 (5–8)

6 (4–8)

0.8

7 (4–8)

7 (4–9)

0.9

8 (6–9)

7 (6–7)

0.4

7 (5–7)

6 (2–7)

0.9

  1. AIT allergy immunotherapy, AR allergic rhinoconjunctivitis, HDM house dust mite, IQR interquartile range, OA oral antihistamines, RQLQ rhinoconjunctivitis quality of life questionnaire, SCIT subcutaneous immunotherapy, SLIT sublingual immunotherapy, VAS visual analogue score
  2. P-values between completed and discontinued subgroups using Chi squared Test for nominal and Mann–Whitney U Test for continuous variables. aFisher’s Exact test used as data violates conditions for Chi squared Test
Back to article page

Clinical and Translational Allergy

ISSN: 2045-7022

Contact us